logo

Conjunctivitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The conjunctivitis treatment market is segmented by Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis), Formulation Type, and Geography

Home Industry Reports Healthcare Conjunctivitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts ...

Market Snapshot

allergic-conjunctivitis-treatment-market_Market Summary
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The market studied is expected to grow in the forecast period due to the high number of people suffering from allergic conjunctivitis and the easier availability of the treatment across the globe.

The National Institute of Health has stated in its 2017 report that the prevalence of conjunctivitis is around 6-30% in the general population and up to 30% in the children across the globe. As the disease is very common, treatment for the same is easily available. Most of the time, the disease is self diagnosable and there is the least need of undergoing any diagnostic test for this disease.

Countries like India are also having a high prevalence of conjunctivitis. As per the article published by a journal named Clinical Epidemiology and Global Health, it was found that during the year 2019, the prevalence of allergic conjunctivitis was around 12.22% and the number of men suffering from this disease is higher than that of females in India. The epidemiology of the disease is similar in other Asian countries such as China.

Hence, owing to the high prevalence of the disease, the market studied is expected to have a steady growth over the forecast period.

Scope of the Report

As per the scope of the report, conjunctivitis is an irritation or inflammation of the conjunctiva. The scope of the report includes the type of conjunctivitis and its geographical scenario.

By Disease Type
Allergic Conjunctivitis
Bacterial Conjunctivitis
Viral Conjunctivitis
By Formulation Type
Ointment
Drops
Drugs
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Allergic Conjunctivitis is Expected to Witness a Steady Growth

The allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. The people having allergies are more likely to develop allergic conjunctivitis. As stated by the Asthma and Allergy Foundation of America, approximately 30% of the adults and 40% of the children suffer from allergies in the United States. The diagnosis of the disease is usually done by self. However, if someone is unable to identify the disease, there are certain tests that the doctor performs to understand the disease and its cause. Some of the tests include allergy skin tests, a blood test to see if the patient's body is producing proteins, or antibodies, to protect itself against specific allergens like mold or dust.

Treatment for acute conjunctivitis includes oral or over the counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available in the market easily which are found to provide relief in acute conjunctivitis. Hence, this segment will witness steady growth during the forecast period.

Conjunctivitis - 2

United States Dominate the Market

It has been stated by the National Institue of Health that conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share in the near future.

Conjunctivitis Treatment Market - Growth Rate by Region - image

Competitive Landscape

The market for conjunctivitis treatment includes international as well as local companies. The disease is self diagnosable and does not always need hospitalization. Therefore, people rely on home remedies or over the counter drugs for treatment. The local companies across various countries are doing a good business in this market as the cost of the drug is less and the preference of people about OTC is increasing. 

For instance, Lupin has launched generic conjunctivitis treatment drug, Moxifloxacin Hydrochloride Ophthalmic solution in the United States.

Conjunctivitis - 4

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Number of People Suffering From Conjunctivitis

      2. 4.2.2 Easy Availability of the Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of Alternative Treatments Such as Home Remedies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Allergic Conjunctivitis

      2. 5.1.2 Bacterial Conjunctivitis

      3. 5.1.3 Viral Conjunctivitis

    2. 5.2 By Formulation Type

      1. 5.2.1 Ointment

      2. 5.2.2 Drops

      3. 5.2.3 Drugs

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG

      2. 6.1.2 Bausch & Lomb Incorporated

      3. 6.1.3 Allergan Plc

      4. 6.1.4 NicOx S.A.

      5. 6.1.5 Alembic Pharmaceuticals

      6. 6.1.6 Sanofi S.A.

      7. 6.1.7 Pfizer Inc.

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Conjunctivitis Treatment Market market is studied from 2018 - 2026.

The Conjunctivitis Treatment Market is growing at a CAGR of 4.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Novartis International AG, Bausch & Lomb Incorporated, Allergan, NicOx S.A., Alembic Pharmaceuticals are the major companies operating in Conjunctivitis Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!